Keskeiset käsitteet
Improved screening and treatments significantly reduce breast cancer mortality rates.
Tiivistelmä
The content discusses the decline in breast cancer mortality rates in the United States between 1975 and 2019, attributing it to advancements in screening and treatments. The Cancer Intervention and Surveillance Modeling Network (CISNET) developed simulation models to quantify the impact of these interventions on mortality rates. Key highlights include:
- Decline in breast cancer mortality rates in the US from 1975 to 2019.
- Contribution of therapeutic advances to the decline.
- Analysis of mortality trends based on ER/ERBB2 status.
- Comparison of mortality rates with and without interventions.
- Breakdown of mortality reduction percentages attributed to different interventions.
- Survival gains in metastatic forms based on ER/ERBB2 status.
- Limitations of the study, including data precision and disparities consideration.
- Conclusion on the impact of screening and treatment on breast cancer mortality.
Tilastot
Between 1975 and 2019, breast cancer mortality in the US decreased significantly.
The overall absolute reduction in mortality was 58% due to screening and various treatments.
29% of the mortality decline was attributed to treating metastatic forms.
47% to recent treatments for stages I-III.
25% to mammography screening.
Lainaukset
"Therapeutic advances played a pivotal role in the decline in breast cancer mortality rates."
"Approximately 25% of the observed decline can be attributed to the treatment of metastatic forms."